Indoleamine 2,3 dioxygenase in intestinal disease

Current Opinion in Gastroenterology

Volumn 29, Issue 2, 2013, Pages 146-152

  Ciorba, Matthew A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

biomarker; cancer; colitis; IDO; kynurenine; tryptophan

Indexed keywords

ABATACEPT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 27; KYNURENINE; TOLL LIKE RECEPTOR 9; TRYPTOPHAN; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; COLITIS; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CROHN DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENTERITIS; ENTEROPATHY; ERYTHROCYTE SEDIMENTATION RATE; GENE EXPRESSION; GENOTYPE; GOBLET CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; INTESTINAL SECRETIONS; LAMINA PROPRIA; LYMPHOCYTIC INFILTRATION; NEGATIVE FEEDBACK; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; REVIEW; TRYPTOPHAN METABOLISM; ULCERATIVE COLITIS;

ANIMALS; BIOLOGICAL MARKERS; COLITIS; COLONIC NEOPLASMS; GASTROINTESTINAL DISEASES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATORY BOWEL DISEASES; INTESTINAL DISEASES; MICE; TUMOR MARKERS, BIOLOGICAL;

EID: 84873413184     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835c9cb3     Document Type: Review

References (70)

1. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007; 396:203-213.
2. Metz R, Duhadaway JB, Kamasani U, et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67:7082-7087.
3. Fukunaga M, Yamamoto Y, Kawasoe M, et al. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: The absence of IDO1 upregulates IDO2 expression in the epididymis. J Histochem Cytochem 2012.
4. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: Beyond IDO and tryptophan depletion. Cancer Res 2012; 72:5435-5440.
5. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478:197-203.
6. Munn DH, Shafizadeh E, Attwood JT, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-1372.
7. Munn DH, ZhouM, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193.
8. Pallotta MT, Orabona C, Volpi C, et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 2011; 12:870-878.
9. Barcelo-Batllori S, Andre M, Servis C, et al. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: Implications for inflammatory bowel diseases. Proteomics 2002; 2:551-560.
10. Ferdinande L, Demetter P, Perez-Novo C, et al. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int J Immunopathol Pharmacol 2008; 21:289-295.
11. Dieckgraefe BK, Stenson WF, Korzenik JR, et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics 2000; 4:1-11.
12. Wolf AM, Wolf D, Rumpold H, et al. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol 2004; 113:47-55.
13. Hansen JJ, Holt L, Sartor RB. Gene expression patterns in experimental colitis in IL-10-deficient mice. Inflamm Bowel Dis 2009; 15:890-899.
14. Gurtner GJ, Newberry RD, Schloemann SR, et al. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003; 125:1762-1773.
15. Matteoli G, Mazzini E, Iliev ID, et al. Gut CD103 dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 2010; 59:595-604.
16. McDole JR, Wheeler LW, McDonald KG, et al. Goblet cells deliver luminal antigen to CD103 dendritic cells in the small intestine. Nature 2012; 483:345-349.
17. Bell LV, Else KJ. Regulation of colonic epithelial cell turnover by IDO contributes to the innate susceptibility of SCID mice to Trichuris muris infection. Parasite Immunol 2011; 33:244-249.
18. Ciorba MA, Bettonville EE, McDonald KG, et al. Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 2010; 184:3907-3916.
19. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood 2008; 111:3257-3265.
20. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009; 114:5062-5070.
21. Harrington L, Srikanth CV, Antony R, et al. Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis. Infect Immun 2008; 76:3045-3053.
22. Cherayil BJ. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis 2009; 15:1391-1396.
23. Katakura K, Lee J, Rachmilewitz D, et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005; 115:695-702.
24. Coquerelle C, Oldenhove G, Acolty V, et al. Anti-CTLA-4 treatment induces IL-10-producing ICOS regulatory T cells displaying IDO-dependent antiinflammatory properties in a mouse model of colitis. Gut 2009; 58:1363-1373.
25. Davis PM, Nadler SG, Stetsko DK, Suchard SJ. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 2008; 126:38-47.
26. Sandborn WJ, Colombel JF, Sands BE, et al. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012; 143:62.e4-69.e4.
27. Mellor AL, Keskin DB, Johnson T, et al. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002; 168:3771-3776.
28. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-774.
29. Mellor AL, Baban B, Chandler PR, et al. Cutting edge: CpG oligonucleotides induce splenic CD19 dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 2005; 175:5601-5605.
30. Gupta NK, Thaker AI, Kanuri N, et al. Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity. Inflamm Bowel Dis 2012; 18:1214-1220.
31. MacKenzie CR, Heseler K, Muller A, Daubener W. Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: Tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab 2007; 8:237-244.
32. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007; 56:61-72.
33. Diegelmann J, Olszak T, Goke B, et al. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. J Biol Chem 2012; 287:286-298.
34. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487:477-481.
35. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012; 159:313-325.
36. Mendoza JL, Abreu MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians. Gastroenterol Clin Biol 2009; 33 (Suppl. 3):S158-S173.
37. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006; 364:82-90.
38. Torres MI, Lopez-Casado MA, Lorite P, Rios A. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease. Clin Exp Immunol 2007; 148:419-424.
39. Beeken WL. Serum tryptophan in Crohn's disease. Scand J Gastroenterol 1976; 11:735-740.
40. Hisamatsu T, Okamoto S, Hashimoto M, et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profiles for the diagnosis and assessment of inflammatory bowel disease. PLoS One 2012; 7:e31131.
41. Shiomi Y, Nishiumi S, Ooi M, et al. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 2011; 17:2261-2274.
42. Forrest CM, Gould SR, Darlington LG, Stone TW. Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv Exp Med Biol 2003; 527:395-400.
43. Forrest CM, Youd P, Kennedy A, et al. Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. J Biomed Sci 2002; 9:436-442.
44. Lin HM, Barnett MP, Roy NC, et al. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. J Proteome Res 2010; 9:1965-1975.
45. Lin HM, Edmunds SI, Helsby NA, et al. Nontargeted urinary metabolite profiling of a mouse model of Crohn's disease. J Proteome Res 2009; 8:2045-2057.
46. Otter D, Cao M, Lin HM, et al. Identification of urinary biomarkers of colon inflammation in IL10-/- mice using short-column LCMS metabolomics. J Biomed Biotechnol 2011; 2011:974701.
47. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7:15-29.
48. Stidham RW, Higgins PD. Value of mucosal assessment and biomarkers in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4:285-291.
49. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-422.
50. Zhou L, Chen H, Wen Q, Zhang Y. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012; 24:695-701.
51. Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115:3520-3530.
52. Huang A, Fuchs D, Widner B, et al. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002; 86:1691-1696.
53. Walczak K, Dabrowski W, Langner E, et al. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol 2011; 46:903-912.
54. Munn DH. Blocking IDO activity to enhance antitumor immunity. Front Biosci (Elite Ed) 2012; 4:734-745.
55. Ferdinande L, Decaestecker C, Verset L, et al. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012; 106:141-147.
56. Brandacher G, Perathoner A, Ladurner R, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12:1144-1151.
57. Gao YF, Peng RQ, Li J, et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 2009; 7:71.
58. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-1274.
59. Chang MY, Smith C, Duhadaway JB, et al. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther 2011; 12:1050-1058.
60. Macho Fernandez E, Valenti V, Rockel C, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011; 60:1050-1059.
61. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331:337-341.
62. Jia L, Schweikart K, Tomaszewski J, et al. Toxicology and pharmacokinetics of 1-methyl-D-tryptophan: Absence of toxicity due to saturating absorption. Food Chem Toxicol 2008; 46:203-211.
63. Soliman HH, Neuger A, Noyes D, et al. A phase I study of 1-methyl-Dtryptophan in patients with advanced malignancies. J Clin Oncol 2012; 30(suppl.; abstr. 2501).
64. Koblish HK, Hansbury MJ, Bowman KJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9:489-498.
65. Newton RC, Scherle PA, Bowman K, et al. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. J Clin Oncol 2012; 30:(abstr. 2500).
66. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2012.
67. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9:46-56.
68. O'Connor JC, Lawson MA, Andre C, et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009; 182:3202-3212.
69. Kim H, Chen L, Lim G, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012; 122:2940-2954.
70. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: A study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997; 32:1013-1021.